Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basel-based Lonza Walkersville and German biotech company Hyglos have signed a mutually beneficial global settlement deal that includes a licensing agreement for endotoxin detection patents.
Subscribe to our email newsletter
According to the deal, Hyglos will leverage Lonza’s patent-protected recombinant factor C technology in the production of endotoxin products.
As part of the settlement, Lonza will cancel a previously filed law suit against Hyglos.
Hyglos general manager Dr Wolfgang Mutter said, "We are convinced that Hyglos’ innovative assays, entirely based on recombinant molecules, are addressing important needs of endotoxin testing laboratories worldwide."
Lonza Bioscience head Dr Teun Van der Heide said, "Endotoxin detection using recombinant factor C instead of Limulus amoebocyte lysates has recently been acknowledged by the FDA as an alternative method. We believe that this sustainable animal-free alternative will be the future of endotoxin detection."